Literature DB >> 23196938

Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.

James H Stein1, Todd T Brown, Heather J Ribaudo, Yun Chen, Mingzhu Yan, Elizabeth Lauer-Brodell, Grace A McComsey, Michael P Dubé, Robert L Murphy, Howard N Hodis, Judith S Currier.   

Abstract

OBJECTIVE: To evaluate associations between traditional cardiovascular disease (CVD) risk factors, inflammatory markers and markers of HIV disease activity with ultrasonographic measures of CVD risk in patients with HIV who are not receiving antiretroviral therapy (ART).
DESIGN: Cross-sectional, baseline evaluation of ART-naive HIV-infected individuals without known CVD or diabetes mellitus enrolled in a randomized ART treatment trial.
METHODS: Prior to ART initiation, carotid artery intima-media thickness (CIMT) and brachial artery flow-mediated dilation (FMD) were measured. Additional parameters included CD4 cell count, HIV viral load, body composition, lipoproteins and inflammatory markers. Associations with common CIMT, bifurcation CIMT, presence of carotid artery lesions and brachial artery FMD were evaluated.
RESULTS: The 331 enrolled individuals were a median (first-third quartile) of 36 (28-45) years old. Common and bifurcation CIMT values were higher and lesions more prevalent with older age (P < 0.001). FMD was lower with older age (P = 0.009). Those with a Framingham Risk Score of at least 6% per 10 years (N = 44) had higher common and bifurcation CIMT (P < 0.001), carotid lesion prevalence (P < 0.001) and lower FMD (P = 0.035). Independent associations with common CIMT were identified for increasing age, height, weight, small low-density lipoprotein (LDL) particles and black race; these were similar for bifurcation CIMT. Presence of carotid artery lesions was associated with increasing age, presence of metabolic syndrome, interleukin-6 and lower HIV-1 RNA.
CONCLUSION: In a contemporary cohort of ART-naive HIV-infected individuals, ultrasonographic measures of CVD risk were more strongly associated with traditional risk factors than CD4 cell counts, HIV replication or inflammatory markers.

Entities:  

Mesh:

Year:  2013        PMID: 23196938      PMCID: PMC3664137          DOI: 10.1097/QAD.0b013e32835ce27e

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  36 in total

1.  Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Authors:  Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

2.  Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

Authors:  Priscilla Y Hsue; Heather J Ribaudo; Steven G Deeks; Tanvir Bell; Paul M Ridker; Carl Fichtenbaum; Eric S Daar; Diane Havlir; Eunice Yeh; Ahmed Tawakol; Michael Lederman; Judith S Currier; James H Stein
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

3.  Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate.

Authors:  James H Stein; Eunice Yeh; Joanne M Weber; Claudia Korcarz; Paul M Ridker; Ahmed Tawakol; Priscilla Y Hsue; Judith S Currier; Heather Ribaudo; Carol K C Mitchell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

Review 4.  Metabolic syndrome, diabetes, and cardiovascular risk in HIV.

Authors:  Linda M Nix; Phyllis C Tien
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 5.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

6.  Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.

Authors:  Michael P Dubé; Lauren Komarow; Carl J Fichtenbaum; Joseph J Cadden; Edgar T Overton; Howard N Hodis; Judith S Currier; James H Stein
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

7.  Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

Authors:  Priya Bhagwat; Ighovwerha Ofotokun; Grace A McComsey; Todd T Brown; Carlee Moser; Catherine A Sugar; Judith S Currier
Journal:  Antivir Ther       Date:  2017-03-01

8.  Association Between the Framingham Risk Score and Carotid Artery Intima-Media Thickness in Patients With Human Immunodeficiency Virus.

Authors:  Kyari Sumayin Ngamdu; Omosalewa O Adewale; Indika Mallawaarachchi; Ogechika K Alozie; Alok K Dwivedi; Deepak L Bhatt
Journal:  Am J Cardiol       Date:  2020-04-22       Impact factor: 2.778

9.  Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.

Authors:  Corrilynn O Hileman; Randi Turner; Nicholas T Funderburg; Richard D Semba; Grace A McComsey
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

10.  Serum amyloid P (SAP) is associated with impaired brachial artery flow-mediated dilation in chronically HIV-1 infected adults on stable antiretroviral therapy.

Authors:  Nath Zungsontiporn; Lishomwa C Ndhlovu; Brooks I Mitchell; James H Stein; Kalpana J Kallianpur; Beau Nakamoto; Sheila M Keating; Philip J Norris; Scott A Souza; Cecilia M Shikuma; Dominic C Chow
Journal:  HIV Clin Trials       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.